JPRN-UMIN000005491已完成未知
PhaseII study of erlotinib in previously treated non-small cell lung cancer (NSCLC) with wild type EGFR - Erlotonib in pre-treated NSCLC with wild type EGFR
Hiroshima citizens hospital Department of Medical Oncology0 个研究点目标入组 40 人开始时间: 2011年4月22日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Radiotherapy to the primary site which is only possible to evaluate 2) superior vena cava syndrome 3) History of severe drug allergy 4) Uncontrolled pleural effusion, ascites, or pericardial effusion 5) History of active infection 6) Uncontrollable diarrhea 7) History of ileus 8) Interstitial pneumonia or pulmonary fibrosis detectable on CT scan 9) Symptomatic eye disease 10) Current or previous(within the last 1 year) history of GI perforation 11) uncontrollable ulcer 12) Symptomatic brain metastases 13) Other active malignancies 14) History of active double cancer 15) Poorly controlled diabetes mellitus 16) History of severe heart disease 17) History of active psychological disease 18) History of pregnancy or lactation 19) Evaluated to be ineligible by a physician for other reasons
研究者
相似试验
已完成
2 期
Phase II study of erlotinib in previously treated non-small cell lung cancer (NSCLC) with wild type EGFR(NEJ006/TCOG0903)Pre-treated non-small cell lung cancer with wild type EGFR and occurred in never or light smokerJPRN-UMIN000002795orth East Japan Study Group /The Tokyo Cooperative Oncology Group43
已完成
2 期
Phase II study of Erlotinib in previously treated advanced non-small cell lung cancer patients with carcinomatous meningitison-small cell lung cancerJPRN-UMIN000007020ung Oncology Group in Kyushu, Japan (LOGIK)32
已完成
2 期
Phase II study of Erlotinib for previously treated advanced or recurrent non-small-cell lung cancer with EGFR wild type and KRAS wild typeadvanced or recurrent non-small-cell lung cancerJPRN-UMIN000008398Gunma Uninersity Hospital30
已完成
2 期
A Phase II Study of Erlotinib for previously treated Non-small cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutatioon-small cell lung cancerJPRN-UMIN000002716Central Japan Lung Study Group (CJLSG)29
已完成
2 期
A Phase II Study of Erlotinib for previously treated Non-small cell Lung Cancer Patients without Epidermal Growth Factor Receptor Mutatioon-small cell lung cancerJPRN-UMIN000002692Central Japan Lung Study Group (CJLSG)54